The Absolute Effect / Oncology Evidence / Evidence Index
TRANSFORM
In transplant-eligible primary refractory or early-relapsed large B-cell lymphoma, does second-line lisocabtagene maraleucel improve EFS over salvage chemotherapy and autologous transplantation?
Registry: NCT03575351 · Evidence reviewed 9 November 2026 · Aliases and follow-up publications consolidated.
Phase III randomized; n=184.Primary-source evidence summaryStudy design, population and eligibility
Phase III randomized; n=184.
Primary refractory or relapse ≤12 months after first-line therapy; eligible for ASCT.
Treatment and comparator
Intervention: Lisocabtagene maraleucel CAR-T, bridging therapy if needed.
Comparator: Platinum salvage immunochemotherapy then high-dose therapy/ASCT in responders.
Endpoints
EFS primary; CR/PFS key secondary.
Key efficacy and clinical outcomes
3-y follow-up: median EFS 29.5 vs 2.4 mo (HR .375); 36-mo EFS 46% vs 19%; primary-analysis CR 74% vs 43%; crossover 66%.
Source-reported outcome visualization
Values are reproduced from the cited report; bars are scaled within this figure. Second-line primary refractory or early-relapsed LBCL ≤12 months · transplant eligible
Median survival and hazard ratios are not fixed-time event risks; NNT is not inferred from them.
Toxicity and treatment burden
CRS and neurotoxicity; grade 3 CRS 1%, grade 3 neurologic events 4% in primary analysis; cytopenias/infections.
Absolute effect and NNT/NNH
Applies to transplant-eligible early relapse/primary refractory disease; not later relapse or transplant-ineligible population.
NNT/NNH is not calculated unless a directly reported, comparable fixed-time risk difference supports it. Median survival and hazard ratios alone do not provide an NNT.
Critical interpretation and limitations
Applies to transplant-eligible early relapse/primary refractory disease; not later relapse or transplant-ineligible population.
This page is an evidence summary, not a substitute for multidisciplinary assessment or patient-specific decision-making.
Current-practice context
Review date: 9 November 2026. Primary publication and selected follow-up sources were reviewed. Full disease-specific guideline, regulatory-label and sequencing audit remains pending; verify current local recommendations and biomarker eligibility before clinical application.